	US 12,453,769 B2
	Pharmaceutical composition and use thereof
Jun Ge, Nanjing (CN); Jianqiang Li, Nanjing (CN); Jiaojiao Sun, Nanjing (CN); Sulin Ren, Nanjing (CN); Tong Zhou, Nanjing (CN); Shiwei Wang, Nanjing (CN); Xiaodong Wang, Nanjing (CN); Jingfeng Huang, Nanjing (CN); and Yue Chen, Nanjing (CN)
Assigned to Grand Theravac Life Sciences (Nanjing) Co., Ltd., Nanjing (CN)
Appl. No. 17/784,086
Filed by Grand Theravac Life Sciences (Nanjing) Co., Ltd., Nanjing (CN)
PCT Filed Dec. 11, 2020, PCT No. PCT/CN2020/135571 § 371(c)(1), (2) Date Jun. 9, 2022, PCT Pub. No. WO2021/115409, PCT Pub. Date Jun. 17, 2021.
Claims priority of application No. 201911279536.0 (CN), filed on Dec. 13, 2019.
Prior Publication US 2023/0076371 A1, Mar. 9, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 31/711 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); A61K 39/29 (2006.01); A61K 39/39 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 31/22 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39 (2013.01) [A61K 31/711 (2013.01); A61K 39/245 (2013.01); A61K 39/29 (2013.01); A61K 39/292 (2013.01); A61P 31/04 (2018.01); A61P 31/12 (2018.01); A61P 31/22 (2018.01); C07K 16/2803 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55577 (2013.01)]

19 Claims

1. A pharmaceutical composition comprising:

i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them, and

ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide,

wherein the sequence of the CpG oligodeoxynucleotide is selected from: CpG T1: TCG TTC GTT CGT TCG TTC GTT (SEQ ID NO: 2); CpG T2: TCG TTC GTT CGT TCG TTC GTT CGT T (SEQ ID NO: 3); and CpG T3: TCG TCG TCG TCG TCG TCG TCG (SEQ ID NO: 4).